Global Infection Control Market in Cancer Therapy: Snapshot
The global infection control market in cancer therapy is prognosticated to register a healthy CAGR during the course of the forecast period 2015–2023 while riding on a surging level of cancer incidences worldwide. With the increasing count of new cancer cases, scientists are feeling the urge to develop more innovative and technologically advanced treatment procedures. As a result, the demand in the market is forecasted to elevate at a telling rate.
Some of the primary factors that could be responsible for the aggressive growth of the global infection control market in cancer therapy include the increasing focus on the requirement of disinfection and sterilization, rising aging population, growing count of surgical procedures, and improving occurrence of hospital-acquired infections (HAIs). One in every 20 infections in the U.S. is an HAI, according to the U.S. Department of Health and Human Services (HSS). Countries such as the U.K. and Japan apart from the U.S. entertain favorable reimbursement policies, which could be a good boost to the overall market.
Furthermore, the rapidly growing global population is prophesied to set the tone for a valuable growth in the global infection control market in cancer therapy. As per the estimates of World Health Organization (WHO), the worldwide elderly population could increase from close to 0.5 bn in 2010 to approximately 2.0 bn by 2050. Infection control and prevention is key for both the doctors and cancer patients receiving treatments. Thus, a perpetual growth could be expected in the market for the coming years.
The various types of treatment options that are commercially available in the market for cancer include traditional surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, photodynamic therapy, stem cell transplant therapy, etc. Among these above-mentioned treatment options, the patients who are receiving chemotherapy are more prone to get infections through their daily activities. One out of every 10 patients who are treated with chemotherapy gets an infection, which needs a hospital visit. Microbes or microorganisms that enter into body of a cancer patient usually acquire these infections and results in illness. The main type of microorganisms causing these infections includes viruses, bacteria, protozoa and some fungal organisms. The infections that are developed in cancer patients can be more harmful than those infections developed in healthy individuals.
According to the Centers for Disease Control and Prevention (CDC), it was estimated that approximately 1.5 million new cases of cancer patients were diagnosed in the United States in year 2010. With improvements in cancer treatment therapies and number of geriatric population in the U.S., the total number of cancer patients is expect to increase in coming years. Even though there is various advancements oncology treatment, infections associated with these therapies remain a major cause of mortality and morbidity in cancer patients. Several factors those are responsible to developing infections in cancer patients including immunosuppresion from their primary cancer and drug therapy treatment. As cancer patients often require the placement of intravascular devices as implanted ports to provide ease with drug therapy infusion for linger period, there is chance of direct portal entry of microorganisms in to the patient body. Thus, proper cancer prevention practices are essential to minimize the risks and complications associated with various cancer treatment therapies. Some of the standard precautions to control the infections associated with cancer therapy include usage of personal protective equipments, hand hygiene procedures, injection safety, proper medication storage and cleaning devices.
The infection control market in cancer therapy is expected to have a huge growth potential in next few years. The contributing factors behind such an assessment include rise in base of geriatric population, increasing number of cancer patients globally and advancements in cancer treatment technologies. Additionally, growing healthcare awareness among the population and poor sanitation conditions in underdeveloped countries further expected to boost the market.
Geographically, North America accounts for the largest share of the infection control market in cancer therapy followed by the European region. The dominance of North America in this market is seen due to rapidly aging population, which can afford high cost cancer treatment and presence of various market leaders that allows easy penetration in the North America region. European infection control market in cancer therapy follows the North America market due to extensive promotion and funding for cancer treatment by the European government such as Germany and the U.K. Asia-Pacific region is expected to witness fastest growth rate in the near future due to rising population base and increasing awareness about the cancer treatment.
Some of the major players operating in this market includes 3M Healthcare Company, Advanced Sterilization Products Services, Inc, Nordion, Inc., Steris Corporation, Synergy Health, Plc, Getinge Group, Ahlstrom Corporation, Honeywell International, Inc., Sakura Global Holding Company, Kimberly Clark Corporation, Cisa S.P.A., Sterigenics International, Inc. and others.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.